Application of liquid biopsy in precision medicine: opportunities and challenges

Precision medicine for cancer patients aims to adopt the most suitable treatment options during diagnosis and treatment of individuals. Detecting circulating tumor cell (CTC) or circulating tumor DNA (ctDNA) in plasma or serum could serve as liquid biopsy, which would be useful for numerous diagnostic applications. Liquid biopsies can help clinicians screen and detect cancer early, stratify patients to the most suitable treatment and real-time monitoring of treatment response and resistance mechanisms in the tumor, evaluate the risk for metastatic relapse, and estimate prognosis.We summarized the advantages and disadvantages of tissue and liquid biopsies.We also further compared and analyzed the advantages and limitations of detecting CTCs, ctDNAs, and exosomes. Furthermore, we reviewed the literature related with the application of serum or plasma CTCs, ctDNAs, and exosomes for diagnosis and prognosis of cancer.We also analyzed their opportunities and challenges as future biomarkers. In the future, liquid biopsies could be used to guide cancer treatment. They could also provide the ideal scheme to personalize treatment in precision medicine.

[1]  Larissa V Furtado,et al.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. , 2015, The Journal of molecular diagnostics : JMD.

[2]  K. Pantel,et al.  Challenges in circulating tumour cell research , 2014, Nature Reviews Cancer.

[3]  Cheng Qian,et al.  Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer , 2016, Oncotarget.

[4]  X. Breakefield,et al.  Brain Tumor Microvesicles: Insights into Intercellular Communication in the Nervous System , 2011, Cellular and Molecular Neurobiology.

[5]  Kenneth J. Pienta,et al.  Circulating Tumor Cells Predict Survival Benefit From Treatment in Metastatic Castration-Resistant Prostate Cancer Editorial Comment , 2009 .

[6]  Maximilian Reichert,et al.  EMT and Dissemination Precede Pancreatic Tumor Formation , 2012, Cell.

[7]  J. Lötvall,et al.  Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells , 2007, Nature Cell Biology.

[8]  Olivier Elemento,et al.  Double-stranded DNA in exosomes: a novel biomarker in cancer detection , 2014, Cell Research.

[9]  Gema Moreno-Bueno,et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2012, Nature Medicine.

[10]  M. Esteller,et al.  DNA methylation profiling in the clinic: applications and challenges , 2012, Nature Reviews Genetics.

[11]  Bert Vogelstein,et al.  DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES , 2014 .

[12]  T. Fehm,et al.  Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials , 2012, Cancer and Metastasis Reviews.

[13]  John W. Park,et al.  Circulating Tumor Cells , 2017, Methods in Molecular Biology.

[14]  R. Tothill,et al.  Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis. , 2016, The Lancet. Oncology.

[15]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[16]  M. Ratajczak,et al.  Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes , 2006, Cancer Immunology, Immunotherapy.

[17]  P. Laird.  Principles and challenges of genome-wide DNA methylation analysis , 2010, Nature Reviews Genetics.

[18]  W. El-Deiry,et al.  Circulating Tumor Cells Versus Circulating Tumor DNA in Colorectal Cancer: Pros and Cons , 2016, Current Colorectal Cancer Reports.

[19]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[20]  J. Thiery,et al.  Exosome-Mediated Metastasis: From Epithelial-Mesenchymal Transition to Escape from Immunosurveillance. , 2016, Trends in pharmacological sciences.

[21]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Johan Skog,et al.  Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. , 2010, Kidney International.

[23]  Tomasz Burzykowski,et al.  Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  T. Schlange,et al.  Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy. , 2016, Pharmacogenomics.

[25]  Christian Pilarsky,et al.  Glypican-1 identifies cancer exosomes and detects early pancreatic cancer , 2015, Nature.

[26]  A. Guha,et al.  Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells , 2008, Nature Cell Biology.

[27]  J. Herman,et al.  The Epigenetic promise for prostate cancer diagnosis , 2012, The Prostate.

[28]  Matthew W. Snyder,et al.  Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin , 2016, Cell.

[29]  Michael Morse,et al.  Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Daniel F. Hayes,et al.  Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer , 2013 .

[31]  Johan Skog,et al.  Liquid biopsy for cancer screening, patient stratification and monitoring , 2018 .

[32]  S. Jeffrey,et al.  Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis? , 2013, Genome Medicine.

[33]  F. Nicolantonio,et al.  Liquid biopsy: monitoring cancer-genetics in the blood , 2013, Nature Reviews Clinical Oncology.

[34]  Alison Stopeck,et al.  Circulating tumor cells, disease progression, and survival in metastatic breast cancer. , 2004, The New England journal of medicine.

[35]  M. Stroun,et al.  Isolation and characterization of DNA from the plasma of cancer patients. , 1987, European journal of cancer & clinical oncology.

[36]  Ed Yong,et al.  Cancer biomarkers: Written in blood , 2014, Nature.

[37]  K. Pantel,et al.  Liquid biopsy: Potential and challenges , 2016, Molecular oncology.

[38]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[39]  Peiyong Jiang,et al.  Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. , 2013, Clinical chemistry.

[40]  Klaus Pantel,et al.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.

[41]  Marius Ilie,et al.  Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? , 2014, Annals of translational medicine.

[42]  Bob S Carter,et al.  RNA expression patterns in serum microvesicles from patients with glioblastoma multiforme and controls , 2012, BMC Cancer.

[43]  Z. Werb,et al.  Circulating Tumor Cells , 2013, Science.